ECOFIBRE LIMITED (EOF)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
EOF - ECOFIBRE LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.86
Index:
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.20
26 May |
OPEN $0.20 |
HIGH $0.21 |
114,574 LOW $0.20 |
0.005| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AHZ . ANP . ARX . AVH . BIO . BNO . BOT . CAU . CSL . CUV . FTT . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TFC . TIS . TLX . TRP . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -4.4 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 30.2 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 32.8 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -10.6 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -48.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -13.23 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -11.76 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -10.07 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -13.23 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -17.65 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -13.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 17 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 20 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 51 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 7 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.61 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 2.8 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 9.24 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 36 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 16 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 6 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EOF STOCK CHART
FNArena News on EOF
| 1 |
Weekly Ratings, Targets, Forecast Changes – 12-02-21Feb 15 2021 - Weekly Reports |
| 2 |
FNArena Corporate Results Monitor – 12-02-2021Feb 12 2021 - Australia |
| 3 |
FNArena Corporate Results Monitor – 06-02-2020Feb 06 2020 - Australia |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: Chimeric TherapeuticsMay 26 2023 - Small Caps |
| 2 |
Avita Medical Preps For Enlarged US OpportunityMay 17 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Radiopharm TheronosticsApr 13 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Avita MedicalMar 29 2023 - Small Caps |
| 5 |
Telix Pharmaceuticals’ Pipeline Full Of PromiseMar 21 2023 - Small Caps |
| 6 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
| 8 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
| 9 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
| 10 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |
